Form 4: Precision BioSciences CFO John Alexander Kelly Acquires Shares in Private Placement

John Alexander Kelly, CFO of Precision BioSciences, acquired 8,334 shares of common stock through a private placement on May 8, 2024.

Summary

• On May 8, 2024, John Alexander Kelly, the Chief Financial Officer of Precision BioSciences, acquired 8,334 shares of the company's common stock.
• The shares were purchased at a price of $12 per share through a non-brokered private placement.
• Following the transaction, Kelly directly owns 31,014 shares of Precision BioSciences.
• The purchase was made pursuant to a definitive subscription agreement with certain members of management.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the CFO's purchase indicates confidence in the company. However, it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• The CFO's purchase of shares could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider buying is often viewed as a positive sign, suggesting that a company's management believes the stock is undervalued. This transaction could be compared to other insider transactions within the biotechnology industry to gauge overall sentiment.

Comparison to Industry Standards

• Comparing this insider purchase to similar transactions at comparable biotech companies could provide context.
• For example, if other CFOs at companies like CRISPR Therapeutics or Editas Medicine have recently purchased shares, it could indicate a broader positive sentiment towards the gene editing sector.
• Conversely, a lack of insider buying across the industry might suggest more caution.

Stakeholder Impact

• The CFO's stock purchase could positively influence shareholder sentiment.

Key Dates